Quarterly Report · 10-Q
Abpro Holdings, Inc
Quarterly Report
Filed May 20, 2026Accepted May 20, 2026, 5:21 PM EDTCIK 1893219Accession 0001213900-26-059646
Company context
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using Abpro’s proprietary DiversImmune® platform. Abpro is located in Burlington, Massachusetts. For more information, please visit www.abpro.co.
Current securities
Historical securities (7)
Registered securities in this filing
Abpro Holdings, Inc. · 10-Q · Filed 2026-05-20
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, $0.0001 par value per share
- Symbol
- ABPO
- Exchange
- NONE
- Classification
- COMMON
Filing context
Context: c1
Dimensions: us-gaap:StatementClassOfStockAxis
Warrants to purchase Common Stock
- Symbol
- ABPWW
- Exchange
- NONE
- Classification
- WARRANT
Filing context
Context: c2
Dimensions: us-gaap:StatementClassOfStockAxis
Accession 000121390026059646 · 2 registered-security cover members
Read the exact SEC filing ↗As-filed source
Primary evidence